Short answer
COLLEGIUM PHARMACEUTICAL, INC (COLL) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $200M (up 6.3% year over year) with net income of −$15M.
Q2 2026 key financials · XBRL
- Revenue
- $200M
- +6.3% YoY · +3.3% QoQ
- Net income
- −$15M
- −225.6% YoY · −203.8% QoQ
- Operating margin
- 1.9%
- Gross margin
- 55.2%
- EPS (diluted)
- −$0.42
- −213.5% YoY · −205.0% QoQ
Source: XBRL data from the COLLEGIUM PHARMACEUTICAL, INC (COLL) Q2 2026 10-Q on SEC EDGAR. USD.
COLLEGIUM PHARMACEUTICAL, INC Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $199.9M vs $188.0M, up $11.9M YoY
- Net loss $15.1M vs net income $12.0M; operating margin 1.9% vs 18.7%
- Best performer Jornay PM, revenue up $13.4M; worst Nucynta Products, revenue down $11.1M
- Cash $129.5M; operating cash flow $128.4M for six months vs $127.8M
- Azstarys acquisition consumed $655.4M cash; management expects liquidity to fund operations for the foreseeable future
Risk Factors
- Newly triggered FDA labeling changes following July 31, 2025 opioid safety announcement, including dosing, discontinuation, overdose, and interaction warnings
- Most materially updated promotional-compliance risk following September 2025 FDA scrutiny and numerous warning letters targeting allegedly misleading pharmaceutical advertising
- Regulatory risk from mandatory Opioid Analgesic REMS, with FDA modifications potentially increasing commercialization costs and reducing prescribing
- Near-term operational risk from heightened competition, generic approvals, and physician or payer acceptance affecting product sales
- Financial risk from $865.5 million term loan, $241.5 million convertible notes, and unhedged floating-rate SOFR exposure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other COLLEGIUM PHARMACEUTICAL, INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.